BioCentury
ARTICLE | Company News

Agios, Celgene deal

May 4, 2015 7:00 AM UTC

The companies partnered to develop and commercialize AG-881 worldwide. Agios said it expects a Phase I trial of the inhibitor of mutated isocitrate dehydrogenase 1 (IDH1) and IDH2 to begin this qua...